On April 27, 2023 Brenus Pharma reported two groundbreaking presentations on STC-1010, the company’s first drug candidate for colorectal cancer (CRC), produced by Brenus Pharma’s STC (Stimulated Tumor-Cells) Technology Platform (Press release, Brenus Pharma, APR 27, 2023, View Source [SID1234630644]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Innovative models for anti-tumor vaccine development were highlighted: Inovotion’s CAM (chorioallantoic model) in-ovo assay and Explicyte’s ex-vivo co-cultured assay, were used to characterize the mechanism of action through a specific immune response, and validate the anti-tumor effects of STC-1010.
These models comply with the FDA’s modernization act 2.0 S. 5002 and demonstrate the potential of STC-1010 in clinical settings for the treatment of patients with colorectal cancer.
The first study evaluated the safety and efficacy of STC-1010 in activating the antitumoral immune response against human colorectal adenocarcinoma using the chicken CAM assay. Results obtained in-ovo confirmed the anti-tumor efficacy -mediated by cytokine secretion and T cells expansion- of the vaccine previously observed in CRC syngeneic mouse models. Dendritic cells primed by STC-1010 will induce a multi specific pool of T-lymphocytes against the tumor without toxicity.
The second study evaluated the functional activity of STC-1010-primed dendritic cells (DCs) from PBMCs human donors’ isolation, to activate autologous CD8+ T cells and promote tumor cell death. The study evaluated the cross-priming and specificity of the immune response induced by STC-1010. Results showed that STC-1010 is an efficient strategy to educate the immune system by cross-priming DCs and increasing the activity of specific CD8+ T cells (TCR sequencing) all of which promotes the significant tumor killing observed ex-vivo.
Taken together, these studies provide promising results for the development of the STC-1010 and prove its potential to be presented into clinical setting for the treatment of patients with CRC.
Innovative in vivo model for anti-tumor vaccine development: Safety validation and preliminary efficacy evaluation of a new antitumor vaccine STC-1010 on human colorectal adenocarcinoma using the chicken CAM assay.
Session Title: Clinical Research Excluding Trials – Vaccines
Abstract Presentation Number: 6791
Yan WANG, [email protected] Scientist/R&D Project Manager2 (PhD)
Arnaud PEYRONNIER, [email protected], Sales Director4 (MSc)
Benoit PINTEUR, [email protected], Chief Scientific Officer3 (Pharm D)
Lionel CHALUS, [email protected], Chief Scientific Officer5
Corinne TORTORELLI, [email protected], Medical Lead5 (Pharm. D., Ph.D)
Paul BRAVETTI, [email protected], Chief Executive Officer5 (Pharm D, MSc)
Jean VIALLET, [email protected], Chief Executive Officier4 (PhD)
François GHIRINGHELLI [email protected], Head of Team Inserm 1231 TIRECs « Therapies and Immune REsponse in CancerS », Director of early clinical unit CLIPP2, Professor of Oncology4 (M.D, PhD)
STC-1010 a new therapeutic vaccine promotes tumor cell death.
Session Title: Late-Breaking Research: Immunology 2
Abstract Presentation Number: LB224
Alban BESSEDE, [email protected], Chief Executive Officer5 (Ph.D)
George ALZEEB, [email protected], Scientific Project Manager5 (Ph.D)
Corinne TORTORELLI, [email protected], Medical Lead5 (Pharm.D., Ph.D)
Jean-Philippe GUEGUAN, [email protected], Study Director7
Christophe REY, [email protected]
Lionel CHALUS, [email protected], Chief Scientific Officer5
Benoit PINTEUR, [email protected], Chief Scientific Officer5 (Pharm D)
Paul BRAVETTI, [email protected],Chief Executive Officer5(Pharm D, MSc)
Antoine ITALIANO, [email protected], Early Phase Trials and Sarcoma Units,6(M.D, Ph.D)